UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists

Journal of endocrinological investigation, 2022-01, Vol.45 (1), p.215-220

2022

Volltextzugriff (PDF)

Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors

Biomedicine & pharmacotherapy, 2023-12, Vol.168, p.115661-115661, Article 115661

2023

Volltextzugriff (PDF)

FINERENONE REDUCES INTRINSIC ARTERIAL STIFFNESS IN A HYPERTENISVE NON-DIABETIC RAT MODEL OF CHRONIC KIDNEY DISEASE

Journal of hypertension, 2019-07, Vol.37, p.e89-e90

2019

Volltextzugriff (PDF)

Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists

Hormone and metabolic research, 2010-06, Vol.42 (6), p.458-465

2010

Volltextzugriff (PDF)

Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

POS-829 Incidence and predictors of hyperkalaemia in patients with CKD and T2D in the FIDELIO-DKD trial

Kidney international reports, 2021-04, Vol.6 (4), p.S360-S361

2021

Volltextzugriff (PDF)

Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

The non-steroidal mineralocorticoid receptor antagonist finerenone improves left ventricular function in preclinical chronic kidney disease

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

P5442The non-steroidal mineralocorticoid receptor antagonist finerenone prevents structural cardiac remodeling

European heart journal, 2019-10, Vol.40 (Supplement_1)

2019

Volltextzugriff (PDF)

Finerenone reduces renal RORgt gd T-Cells and protects against cardiorenal damage

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

P1263The best of two worlds: Vascular protection and decongestion without RAAS stimulation mediated by a novel dual acting V1a/V2 vasopressin receptor antagonist

European heart journal, 2018-08, Vol.39 (suppl_1)

2018

Volltextzugriff (PDF)

P2499Finerenone improves vascular function through a reduction of endothelial dysfunction and arterial stiffness in a genetic rat model of chronic kidney disease

European heart journal, 2018-08, Vol.39 (suppl_1)

2018

Volltextzugriff (PDF)

Sulfenic Acid Modification of ET- B Receptor is Responsible for the Benefit of a Nonsteroidal MR Antagonist in Renal Ischemia

Journal of the American Society of Nephrology, 2016-02, Vol.27 (2), p.398-404

2016

Volltextzugriff (PDF)

POS-350 FINERENONE IN MILD TO SEVERE CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: THE FIDELITY PRESPECIFIED POOLED ANALYSIS

Kidney international reports, 2022-02, Vol.7 (2), p.S157-S158

2022

Volltextzugriff (PDF)

Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors

Biochemical and biophysical research communications, 2002-08, Vol.296 (2), p.343-349

2002

Volltextzugriff (PDF)

L’utilisation d’un antagoniste non stéroïdien du récepteur minéralocorticoïde (BR-4628) prévient les lésions rénales induites par l’ischémie-reperfusion

Néphrologie & thérapeutique, 2015-09, Vol.11 (5), p.447

2015

Volltextzugriff (PDF)

Der Einfluss des neuen nichtsteroidalen Mineralocorticoid Antagonisten BR-4628 auf die Natriumausscheidung bei sekundärer biliärer Leberzirrhose

Zeitschrift für Gastroenterologie, 2010, Vol.48 (8)

2010

Volltextzugriff (PDF)

Aldosterone causes DNA damage in vitro and in kidneys of DOCA/salt rats, mediated by the mineralocorticoid receptor

Toxicology letters, 2009-09, Vol.189, p.S98-S98

2009

Volltextzugriff (PDF)

Einfluss des neuen nichtsteroidalen Mineralocorticoid Antagonisten BR-4628 und des Mineralocorticoid Antagonisten Spironolacton auf die Fibroseentwicklung im BDL Modell der Ratte

Zeitschrift für Gastroenterologie, 2011-08, Vol.49 (8)

2011

Volltextzugriff (PDF)

0316 : Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction

Archives of Cardiovascular Diseases Supplements, 2015-04, Vol.7 (2), p.190-190

2015

Volltextzugriff (PDF)

Quality and position of the three lac operators of E. coli define efficiency of repression

The EMBO journal, 1994-07, Vol.13 (14), p.3348-3355

1994

Volltextzugriff (PDF)

Lac repressor with the helix‐turn‐helix motif of lambda cro binds to lac operator

The EMBO journal, 1992-08, Vol.11 (8), p.3031-3038

1992

Volltextzugriff (PDF)

Specificities of three tight-binding Lac repressors

Nucleic acids research, 1992-10, Vol.20 (19), p.5035-5039

KOLKHOF, P

1992

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(36)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists

Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors

FINERENONE REDUCES INTRINSIC ARTERIAL STIFFNESS IN A HYPERTENISVE NON-DIABETIC RAT MODEL OF CHRONIC KIDNEY DISEASE

Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists

Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?

POS-829 Incidence and predictors of hyperkalaemia in patients with CKD and T2D in the FIDELIO-DKD trial

Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis

The non-steroidal mineralocorticoid receptor antagonist finerenone improves left ventricular function in preclinical chronic kidney disease

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

P5442The non-steroidal mineralocorticoid receptor antagonist finerenone prevents structural cardiac remodeling

Finerenone reduces renal RORgt gd T-Cells and protects against cardiorenal damage

P1263The best of two worlds: Vascular protection and decongestion without RAAS stimulation mediated by a novel dual acting V1a/V2 vasopressin receptor antagonist

P2499Finerenone improves vascular function through a reduction of endothelial dysfunction and arterial stiffness in a genetic rat model of chronic kidney disease

Sulfenic Acid Modification of ET- B Receptor is Responsible for the Benefit of a Nonsteroidal MR Antagonist in Renal Ischemia

POS-350 FINERENONE IN MILD TO SEVERE CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: THE FIDELITY PRESPECIFIED POOLED ANALYSIS

Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors

L’utilisation d’un antagoniste non stéroïdien du récepteur minéralocorticoïde (BR-4628) prévient les lésions rénales induites par l’ischémie-reperfusion

Der Einfluss des neuen nichtsteroidalen Mineralocorticoid Antagonisten BR-4628 auf die Natriumausscheidung bei sekundärer biliärer Leberzirrhose

Aldosterone causes DNA damage in vitro and in kidneys of DOCA/salt rats, mediated by the mineralocorticoid receptor

Einfluss des neuen nichtsteroidalen Mineralocorticoid Antagonisten BR-4628 und des Mineralocorticoid Antagonisten Spironolacton auf die Fibroseentwicklung im BDL Modell der Ratte

0316 : Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction

Quality and position of the three lac operators of E. coli define efficiency of repression

Lac repressor with the helix‐turn‐helix motif of lambda cro binds to lac operator

Specificities of three tight-binding Lac repressors

Aktive Filter

Suchergebnisse filtern